



the **Hydroponics** company

www.thcl.com.au

ASX RELEASE (25<sup>th</sup> June 2018)

## **Inaugural Shipment of Medicinal Cannabis Received from Endoca**

### **Key Points:**

- **First medicinal cannabis products have been received under THC's partnership with leading European supplier Endoca in Denmark**
- **Approved Australian patients will be able to access products under the Government's Special Access Scheme**
- **THC's distribution agreement with Endoca allows for the import of some of the world's highest quality CBD products**
- **Choice for medical practitioners and patients includes CBD-rich product and unique CBD+CBDA product**
- **All products will be available using the Medicinal Cannabis Medicines Portal (MCMP)**

**The Hydroponics Company Limited** ("THC" or "the Company") is pleased to advise that the first medicinal cannabis products have been received from THC's European strategic alliance partner, Endoca.

The initial shipment of medicinal cannabis oils from Endoca will be accessible to patients and healthcare professionals in Australia through the MCMP [www.mcmp.com.au](http://www.mcmp.com.au).

The MCMP significantly streamlines the process required for doctors to prescribe medicinal cannabis to Australian patients via the Special Access Scheme. Supply will be available to the Australian market within weeks.

THC has import permits in place to begin distributing medicinal cannabis products from Endoca and Australian patients will have immediate access under the existing Government Special Access Scheme or through an Approved Prescriber.

The receipt of these products represents a significant development in advancing the medicinal cannabis industry in Australia, and most importantly, making high quality products available to patients in need.

The products will provide medical practitioners with a choice of non-psychoactive cannabis-based products including CBD-rich product and the CBD+CBDA raw product which is unique in Australia.

THC's Chairman Steven Xu said: "THC's program to bring Endoca products to Australia is the first step in providing Australia with high quality medicinal cannabis solutions, which will extend to local organic growing and pharmaceutical GMP manufacture as we roll out our partner and domestic production strategy."



The Hydroponics Company Limited  
(ASX:THC) ACN: 614 508 039

Suite 305, Level 3, 35 Lime Street  
Sydney NSW 2000 Australia

**For further information, please contact:**

Henry Kinstlinger  
Joint Company Secretary  
The Hydroponics Company Limited

Level 2, 131 Macquarie Street  
Sydney, NSW 2000 Australia

**P:** +61 2 9251 7177

**E:** [henry.kinstlinger@thcl.com.au](mailto:henry.kinstlinger@thcl.com.au)



Michael Lovesey  
Director Corporate Media Relations  
MMR Corporate Services Pty Ltd

Level 2, 131 Macquarie Street  
Sydney, NSW 2000 Australia

**P:** +61 2 9251 7177

**M:** +61 449 607 636

**E:** [michaell@mrrcorporate.com](mailto:michaell@mrrcorporate.com)

**About THC** [www.thcl.com.au](http://www.thcl.com.au)

THC is at the forefront of developing a leading, diversified worldwide cannabis business, focusing on two core business units: Development and delivery of medicinal cannabis, and manufacturing and distribution of hydroponics equipment, materials and nutrients.

**About Endoca** [www.endoca.com](http://www.endoca.com)

Endoca's primary focus is to research and develop innovative cannabis extracts that can help to balance the human Endocannabinoid system making them accessible world-wide. Through targeting the human Endocannabinoid System many people can be helped to restore their internal balance. Endoca is dedicated to producing the finest and purest quality products like CBD oil while never compromising on quality. Endoca also produces other cannabinoids as there are over 80 different in nature.